AQB 10-Q Quarterly Report Sept. 30, 2018 | Alphaminr
AquaBounty Technologies, Inc.
ALPHAMINR

AQB 10-Q Quarter ended Sept. 30, 2018

Balance Sheet
Cash Flow
Income Statement
Debt
AQUABOUNTY TECHNOLOGIES, INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-K
Fiscal year ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
PROXIES
DEF 14A
Filed on April 4, 2025
DEF 14A
Filed on April 5, 2024
DEF 14A
Filed on Oct. 12, 2023
DEF 14A
Filed on Sept. 1, 2023
DEF 14A
Filed on April 6, 2023
DEF 14A
Filed on Oct. 12, 2022
DEF 14A
Filed on Aug. 31, 2022
DEF 14A
Filed on May 17, 2022
DEF 14A
Filed on April 14, 2022
DEF 14A
Filed on March 17, 2022
DEF 14A
Filed on April 21, 2021
DEF 14A
Filed on Nov. 5, 2020
DEF 14A
Filed on March 19, 2020
DEF 14A
Filed on March 21, 2019
DEF 14A
Filed on April 3, 2018
DEF 14A
Filed on April 19, 2017
10-Q 1 aqb10-q2018x09x30.htm 10-Q Document
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2018
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________ to _____________________
Commission File Number: 001-36426
AquaBounty Technologies, Inc.
(Exact name of the registrant as specified in its charter)
Delaware
04-3156167
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
2 Mill & Main Place, Suite 395
Maynard, Massachusetts 01754
(978) 648-6000
(Address and telephone number of the registrant’s principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit such files).
Yes þ No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  ☐
Accelerated filer  ☐
Non-accelerated filer þ
Smaller reporting company  ☐
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes  ☐    No þ
At November 1, 2018 , the registrant had 15,098,837 shares of common stock, par value $0.001 per share (“Common Shares”) outstanding.




PART I. FINANCIAL INFORMATION
Item 1.  Financial Statements
AquaBounty Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)
As of
September 30,
December 31,
2018
2017
Assets
Current assets:
Cash and cash equivalents
$
1,030,671

$
492,861

Certificate of deposit
13,040

13,422

Other receivables
81,822

183,926

Inventory
72,640

172,363

Prepaid expenses and other current assets
315,383

527,322

Total current assets
1,513,556

1,389,894

Property, plant and equipment, net
24,001,108

21,802,976

Definite-lived intangible assets, net
174,717

184,995

Indefinite-lived intangible assets
191,800

191,800

Other assets
162,093

162,093

Total assets
$
26,043,274

$
23,731,758

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities
$
1,483,657

$
2,666,855

Current debt
59,636

49,794

Total current liabilities
1,543,293

2,716,649

Long-term debt
2,970,816

3,034,420

Total liabilities
4,514,109

5,751,069

Commitments and contingencies




Stockholders’ equity:
Common stock, $0.001 par value, 50,000,000 shares authorized;
12,848,376 (2017: 8,895,094) shares outstanding
12,848

8,895

Additional paid-in capital
138,333,891

126,718,186

Accumulated other comprehensive loss
(327,102
)
(213,884
)
Accumulated deficit
(116,490,472
)
(108,532,508
)
Total stockholders’ equity
21,529,165

17,980,689

Total liabilities and stockholders’ equity
$
26,043,274

$
23,731,758

See accompanying notes to these unaudited interim consolidated financial statements.

1


AquaBounty Technologies, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2018
2017
2018
2017
Revenues
Product revenues
$
10,938


$
—


$
77,933


$
53,278

Costs and expenses
Product costs
8,874

—

72,393

50,777

Sales and marketing
64,971

195,947

222,999

607,145

Research and development
804,758

860,903

2,663,397

2,517,242

General and administrative
1,852,362

1,382,380

5,067,226

3,453,516

Total costs and expenses
2,730,965

2,439,230

8,026,015

6,628,680

Operating loss
(2,720,027
)
(2,439,230
)
(7,948,082
)
(6,575,402
)
Other income (expense)
Gain on disposal of equipment
—

—

11,745

—

Interest expense
(5,169
)
(5,597
)
(15,854
)
(16,130
)
Other income (expense), net
(1,832
)
(1,392
)
(5,773
)
(3,866
)
Total other income (expense)
(7,001
)
(6,989
)
(9,882
)
(19,996
)
Net loss
$
(2,727,028
)
$
(2,446,219
)
$
(7,957,964
)
$
(6,595,398
)
Other comprehensive income (loss):
Foreign currency translation income (loss)
84,711

34,933

(113,218
)
43,084

Total other comprehensive income (loss)
84,711

34,933

(113,218
)
43,084

Comprehensive loss
$
(2,642,317
)
$
(2,411,286
)
$
(8,071,182
)
$
(6,552,314
)
Basic and diluted net loss per share
$
(0.21
)
$
(0.28
)
$
(0.64
)
$
(0.76
)
Weighted average number of common shares -
basic and diluted
12,848,376

8,895,094

12,528,995

8,731,178

See accompanying notes to these unaudited interim consolidated financial statements.

2


AquaBounty Technologies, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
Common stock issued and outstanding
Par value
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total
Balance at December 31, 2017
8,895,094

$
8,895

$
126,718,186

$
(213,884
)
$
(108,532,508
)
$
17,980,689

Net loss
(7,957,964
)
(7,957,964
)
Other comprehensive loss
(113,218
)
(113,218
)
Issuance of common stock and warrants, net of expenses
3,692,307

3,692

10,612,356

10,616,048

Exercise of warrants for common stock
249,824

250

811,678

811,928

Share based compensation
11,151

11

191,671

191,682

Balance at September 30, 2018
12,848,376

$
12,848

$
138,333,891

$
(327,102
)
$
(116,490,472
)
$
21,529,165

See accompanying notes to these unaudited interim consolidated financial statements.

3


AquaBounty Technologies, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
2018
2017
Operating activities
Net loss
$
(7,957,964
)
$
(6,595,398
)
Adjustment to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization
557,718

137,229

Share-based compensation
191,682

85,443

Gain on disposal of equipment
(11,745
)
—

Changes in operating assets and liabilities:
Other receivables
97,353

(43,346
)
Inventory
97,897

(78,499
)
Prepaid expenses and other assets
210,796

(309,986
)
Accounts payable and accrued liabilities
(654,997
)
128,917

Net cash used in operating activities
(7,469,260
)
(6,675,640
)
Investing activities
Purchase of property, plant and equipment
(3,375,306
)
(17,235,184
)
Proceeds on sale of equipment
21,758

—

Net cash used in investing activities
(3,353,548
)
(17,235,184
)
Financing activities
Proceeds from issuance of debt
—

256,807

Repayment of term debt
(43,437
)
(23,677
)
Proceeds from the issuance of common stock and warrants, net
10,616,048

24,989,257

Proceeds from the exercise of stock options and warrants
811,928

27,502

Net cash provided by financing activities
11,384,539

25,249,889

Effect of exchange rate changes on cash and cash equivalents
(23,921
)
54,147

Net change in cash and cash equivalents
537,810

1,393,212

Cash and cash equivalents at beginning of period
492,861

3,324,609

Cash and cash equivalents at the end of period
$
1,030,671

$
4,717,821

Supplemental disclosure of cash flow information and
non-cash transactions:
Interest paid in cash
$
15,854

$
16,130

Property and equipment included in accounts payable and accrued liabilities
$
512,497

$
472,283

Acquisition of equipment under debt arrangement
$
74,555

$
—

See accompanying notes to these unaudited interim consolidated financial statements.

4


AquaBounty Technologies, Inc.
Notes to the consolidated financial statements
For the nine months ended September 30, 2018 and 2017 (unaudited)
1. Nature of business and organization
AquaBounty Technologies, Inc. (the “Parent” and, together with its subsidiaries, the “Company”) was incorporated in December 1991 in the State of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm‑raised Atlantic salmon that exhibit growth rates that are substantially faster than traditional salmon.
In 2015, the Parent obtained approval from the US Food and Drug Administration (the “FDA”) for the production, sale, and consumption of its AquAdvantage® Salmon product in the United States.
In 2016, the Parent obtained approval from Health Canada for the sale and consumption of its AquAdvantage Salmon product in Canada. Previously, in 2013, the Parent obtained approval from Environment Canada for the production of the product.
AQUA Bounty Canada Inc. (the “Canadian Subsidiary”) was incorporated in January 1994 for the purpose of establishing a commercial biotechnology laboratory to conduct research and development programs related to the Parent’s technologies and to commercialize the Parent’s products in Canada.
AquaBounty Panama, S. de R.L. (the “Panama Subsidiary”) was incorporated in May 2008 in Panama for the purpose of conducting commercial trials of the Parent’s products.
AquaBounty Farms, Inc. (the “U.S. Subsidiary”) was incorporated in December 2014 in the State of Delaware for the purpose of conducting field trials and commercializing the Parent’s products in the United States.
AquaBounty Farms Indiana LLC (the “Indiana Subsidiary”), which is wholly owned by the U.S. Subsidiary, was formed in June 2017 in the State of Delaware for the purpose of operating its aquaculture facility in Albany, Indiana.
AquaBounty Brasil Participações Ltda. (the “Brazil Subsidiary”) was incorporated in May 2015 for the purpose of conducting field trials and commercializing the Parent’s products in Brazil.
2. Basis of presentation
The unaudited interim consolidated financial statements include the accounts of AquaBounty Technologies, Inc. and its wholly owned direct subsidiaries, AQUA Bounty Canada Inc.; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC; and AquaBounty Brasil Participações Ltda. All inter-company transactions and balances have been eliminated upon consolidation.
The unaudited interim consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2017. The unaudited interim consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position as of September 30, 2018 , and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited interim consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.
Net loss per share
Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Basic net loss is based solely on the number of common shares outstanding during the period. Fully diluted net loss per share includes the number of shares of common stock issuable upon the exercise of warrants and options with an exercise price less than the fair value of the common stock. Since the Company is reporting a net loss for all periods presented, all potential common shares are considered anti‑dilutive and are excluded from the calculation of diluted net loss per share.
Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-02, “Leases,” which requires a lessee to recognize lease liabilities for the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and right-of-use assets, representing the lessee’s right to use, or control the use of, specified assets for the lease term. Additionally, the new guidance has simplified accounting for sale and leaseback transactions. Lessor accounting is

5


largely unchanged. The ASU is effective for fiscal years beginning after December 15, 2018. The Company is continuing its evaluation of the impact on its consolidated financial statements.
In February 2018, FASB issued ASU 2018-02, “Income Statement-Reporting Comprehensive Income” which provides guidance on the impact to comprehensive income from changes due to the 2017 Tax Cuts and Jobs Act. The Company is currently reviewing the guidance, which is effective for fiscal years beginning after December 15, 2018.
Management does not expect any recently issued, but not yet effective, accounting standards to have a material effect on its results of operations or financial condition.
Liquidity and Management’s Plan
At September 30, 2018 , the Company’s cash balance totaled $1.0 million . Management has evaluated the Company’s cash resources as of the date of issuance, including the proceeds from the warrant exercise as disclosed in Note 11, in view of its planned spending for ongoing operations, capital expenditures, and working capital for the next twelve months and has determined that its current funds will be used during the first half of 2019 primarily due to increased working capital requirements. However, management believes that the Company can continue as a going concern.
Management’s assessment is based primarily on its ability and past experience in managing expenditures in order to conserve the Company’s cash. Management has the ability to reduce expenditures, slow-down or delay capital spending and divest assets in order to extend cash through the next twelve months.
In addition, the Company continues to seek additional financing in the form of debt or equity. However, there is no assurance the Company can be successful in securing additional financing.
Management believes it is probable that its plans will be effectively implemented and therefore, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
3. Risks and uncertainties
The Company is subject to risks and uncertainties common in the biotechnology and aquaculture industries. Such risks and uncertainties include, but are not limited to: (i) results from current and planned product development studies and trials; (ii) decisions made by the FDA or similar regulatory bodies in other countries with respect to approval and commercial sale of any of the Company’s proposed products; (iii) the commercial acceptance of any products approved for sale and the Company’s ability to manufacture, distribute, and sell for a profit any products approved for sale; (iv) the Company’s ability to obtain the necessary patents and proprietary rights to effectively protect its technologies; and (v) the outcome of any collaborations or alliances entered into by the Company. In addition, as disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10‑K for the year ended December 31, 2017, which was filed on March 8, 2018, there are a number of other risks and uncertainties that may have a material effect on the operating results of our business and our financial condition.
Concentration of credit risk
Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and certificates of deposit. This risk is minimized by the Company’s policy of investing in financial instruments with short-term maturities issued by highly rated financial institutions. The Company’s cash balances may at times exceed insurance limitations. The Company holds cash balances in bank accounts located in Canada to fund its local operations. These amounts are subject to foreign currency exchange risk, which is mitigated by the Company’s policy to limit the balances held in these accounts. Balances in Canadian bank accounts totaled $111,771 at September 30, 2018 .
Financial instruments
The carrying amounts reported in the consolidated balance sheets for other receivables and accounts payable approximate fair value based on the short-term maturity of these instruments. The carrying value of term debt approximates its fair value, since it provides for market terms and interest rates.

6


4. Inventory
Major classifications of inventory are summarized as follows:
September 30,
December 31,
2018
2017
Feed
$
35,871

$
60,161

Eggs
—

73,967

Packaging
8,913

—

Fish in process
27,856

38,235

Total inventory
$
72,640

$
172,363

5. Property, plant and equipment
Major classifications of property, plant and equipment are summarized as follows:
September 30,
December 31,
2018
2017
Land
$
719,949

$
676,083

Building and improvements
9,352,175

9,187,160

Construction in process
5,991,663

5,119,961

Equipment
9,779,714

8,211,510

Office furniture and equipment
191,654

136,091

Vehicles
28,335

29,135

Total property and equipment
$
26,063,490

$
23,359,940

Less accumulated depreciation and amortization
(2,062,382
)
(1,556,964
)
Property, plant and equipment, net
$
24,001,108

$
21,802,976

Depreciation and amortization expense was $574,440 and $126,951 for the nine months ended September 30, 2018 and 2017 , respectively.
Included in construction in process is $5.6 million for renovation and new construction costs incurred at our Rollo Bay farm site. An additional $1.0 million has been committed. The grow-out building is expected to be completed by year end, and the broodstock building is expected to be completed during 2019.
On June 22, 2017, the Company purchased the aquaculture facility of Bell Fish Company LLC in Albany, Indiana, for $14.2 million , including legal and other expenses incurred. Through September 30, 2018, the Company has invested $2.3 million to upgrade the facility for use to grow out its AquAdvantage Salmon for harvest and sale in the United States. The Company currently has an additional $100 thousand committed to this project. This facility is now operational, although the Company expects that upgrades will continue through 2019.
6. Accounts payable and accrued liabilities
Accounts payable and accrued liabilities include the following:
September 30,
December 31,
2018
2017
Accounts payable
$
718,861

$
1,089,919

Accrued payroll including vacation
320,536

364,368

Accrued professional fees and research costs
246,645

443,178

Accrued franchise and excise taxes
55,611

240,880

Accrued construction costs
107,215

509,950

Accrued other
34,789

18,560

Accounts payable and accrued liabilities
$
1,483,657

$
2,666,855


7


7. Debt
The current material terms and conditions of debt outstanding are as follows:
Original loan amount
Interest
rate
Monthly
repayment
Maturity
date
September 30, 2018
December 31, 2017
ACOA AIF grant (C$2,871,919)
0%
Royalties
-
$
2,224,876

$
2,287,771

ACOA term loan (C$337,000)
0%
C$3,120
June 2026
222,401

251,056

Kubota Canada Ltd. (C$95,961)
0%
C$1,142
January 2025
67,261

—

Finance PEI term loan (C$717,093)
4%
C$4,333
July 2021
515,914

545,387

Total debt
$
3,030,452

$
3,084,214

less: current portion
(59,636
)
(49,794
)
Long-term debt
$
2,970,816

$
3,034,420

Estimated principal payments remaining on loan debt are as follows:
Year
AIF
ACOA
FPEI
Kubota
Total
2018
$
—

$
7,251

$
4,942

$
2,655

$
14,848

2019
—

29,005

20,211

10,620

59,836

2020
—

29,005

21,033

10,620

60,658

2021
—

29,005

469,728

10,620

509,353

2022
—

29,005

—

10,620

39,625

Thereafter
2,224,876

99,130

—

22,126

2,346,132

Total
$
2,224,876

$
222,401

$
515,914

$
67,261

$
3,030,452

Atlantic Canada Opportunities Agency (“ACOA”)
ACOA is a Canadian government agency that provides funding to support the development of businesses and promote employment in the Atlantic region of Canada.
In January 2009, the Canadian Subsidiary was awarded an Atlantic Innovation Fund (“AIF”) grant from ACOA to provide a contribution towards the funding of a research and development project. Contributions under the grant were made through 2014 and no further funds are available. Amounts claimed by the Canadian Subsidiary must be repaid in the form of a 10% royalty on any products that are commercialized out of this research project until the loan is fully repaid. Revenue from the sale of AquAdvantage Salmon are not subject to the royalty, and the Company does not expect to commercialize products that would be subject to the royalty in the next five years.
In February 2016, the Canadian Subsidiary executed an agreement with ACOA to partially finance the renovations to the Rollo Bay farm site. All available funding under the agreement was disbursed through May 2017, and no further amounts are available. The loan is being repaid over a period of nine years.
Kubota Canada Ltd. (“Kubota”)
Kubota is a manufacturer of power equipment for the construction, agriculture, commercial, and residential industries. In January 2018, the Canadian Subsidiary financed the purchase of equipment through a lease with Kubota. The total amount financed was $75,911 and is being repaid in monthly installments. The loan is secured by the underlying equipment.
Finance PEI (“FPEI”)
FPEI is a corporation of the Ministry of Economic Development and Tourism for Prince Edward Island, Canada, and administers business financing programs for the provincial government. In August 2016, the Canadian Subsidiary obtained a loan from FPEI to partially finance the purchase of the assets of the former Atlantic Sea Smolt plant in Rollo Bay West on Prince Edward Island. The loan is being repaid through monthly payments of principal and interest with a balloon payment for the balance due in July 2021. The loan is collateralized by a mortgage executed by the Canadian Subsidiary, which conveys a first security interest in all of its current and acquired assets. The loan is guaranteed by the Parent.
The Company recognized interest expense of $15,782 and $16,112 for the nine months ended September 30, 2018 and 2017 , respectively, on its interest-bearing debt.

8


8. Stockholders’ equity
In May 2018, the Company’s shareholders approved a reduction in the number of authorized shares of stock from 240 million to 55 million , of which 5 million are authorized as preferred stock and 50 million as common stock.
Recent issuances
In January 2018, the Company completed a public offering of 3,692,307 Common Shares and warrants for 4,246,153 Common Shares. Net proceeds to the Company were $10.6 million after deducting discounts, fees, and expenses. Intrexon Corporation, the Company’s majority shareholder, participated in the offering, purchasing 1,538,461 Common Shares and warrants for 1,538,461 Common Shares for gross proceeds of $5.0 million .
As of September 30, 2018 , the Company has issued 249,824 Common Shares in conjunction with the exercise of warrants, with total proceeds of $811,928 .
Warrants
In connection with the public offering of Common Shares that was completed in January 2018, the Company issued warrants to purchase 4,246,153 Common Shares. Each warrant has an exercise price per share of $3.25 , is immediately exercisable, and will expire five years from the date of issuance. The following table summarizes information about outstanding warrants at September 30, 2018 :
Number of
warrant shares
Weighted
average
exercise price
Outstanding at December 31, 2017
—

$
—

Issued
4,246,153

3.25

Exercised
(249,824
)
3.25

Outstanding at September 30, 2018
3,996,329


$3.25

Exercisable at September 30, 2018
3,996,329


$3.25

Share-based compensation
Restricted stock
A summary of the Company’s shares of restricted stock as of September 30, 2018 , is as follows:
Shares
Weighted
average grant
date fair value
Balance at December 31, 2017
2,697


$11.37

Granted
11,151

2.50

Vested
(3,645
)
5.63

Balance at September 30, 2018
10,203


$3.73

During the nine months ended September 30, 2018 and 2017 , the Company expensed $20,421 and $19,235 , respectively, related to the restricted stock awards. At September 30, 2018 , the balance of unearned share-based compensation to be expensed in future periods related to the restricted stock awards is $37,891 . The period over which the unearned share-based compensation is expected to be earned is approximately 2.4 years.

9


Stock options
The Company’s option activity is summarized as follows:
Number of
options
Weighted
average
exercise price
Outstanding at December 31, 2017
227,203


$9.39

Issued
113,561

2.50

Expired
(800
)
9.90

Outstanding at September 30, 2018
339,964


$7.09

Exercisable at September 30, 2018
271,467


$7.30

Unless otherwise indicated, options issued to employees, members of the Board of Directors, and non-employees are vested over one to three years and are exercisable for a term of ten years from the date of issuance.
The weighted average fair value of stock options granted during the nine months ended September 30, 2018 , was $1.65 . The total intrinsic value of all options outstanding was $80,628 and $17,454 at September 30, 2018 , and December 31, 2017 , respectively. The total intrinsic value of exercisable options was $47,491 and $17,454 at September 30, 2018 , and December 31, 2017 , respectively.
The following table summarizes information about options outstanding and exercisable at September 30, 2018 :
Weighted average exercise price of outstanding options
Number of options outstanding
Weighted average remaining estimated life (in years)
Number of options exercisable
Weighted average exercise price of outstanding and exercisable options
$2.50 - $5.70
204,034

5.9
157,362

$6.90 - $9.60
53,175

4.0
53,175

$10.50 - $10.80
4,000

5.4
4,000

$14.20 - $23.40
78,755

7.5
56,930

339,964

271,467

$7.30
Total share-based compensation on stock-option grants amounted to $171,261 and $66,208 for the nine months ended September 30, 2018 and 2017 , respectively. At September 30, 2018 , the balance of unearned share-based compensation to be expensed in future periods related to unvested share-based awards was $176,080 . The period over which the unearned share-based compensation is expected to be earned is approximately 1.4 years.
9. Commitments and contingencies
The Company recognizes and discloses commitments when it enters into executed contractual obligations with other parties. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
In May 2018, the Company extended its lease for its Panama farm site for an additional twelve months with total rent payments of $180,000 .
See Note 5 for commitments related to our renovation and construction costs.
There have been no other material changes to the commitments and contingencies disclosed in our annual report on Form 10‑K as of and for the year ended December 31, 2017.
10. Related Party Collaboration Agreement
In February 2013, the Company entered into an Exclusive Channel Collaboration agreement (“ECC”) with Intrexon pursuant to which the Company will use Intrexon’s UltraVector and other technology platforms to develop and commercialize additional genetically modified traits in finfish for human consumption.
Total Intrexon service costs incurred under the terms of this agreement for the nine months ended September 30, 2018 and 2017 , amounted to $163,995 and $447,382 , respectively, and are included as a component of research and development expense in our Consolidated Statements of Operations and Comprehensive Loss. For the three months ended September 30, 2018 and 2017 , service costs incurred amounted to $27,954 and $132,266 , respectively. Included in accounts payable and accrued liabilities at September 30, 2018 , and December 31, 2017 , are amounts due to Intrexon under the ECC totaling $7,800 and $135,301 , respectively.

10


11. Subsequent Events
On October 16, 2018, the Canadian subsidiary obtained a loan from FPEI to finance construction activities at the Rollo Bay site. New funds available amount to C$2.0 million ( $1.6 million ) and the loan has an interest rate of 4% . Payments will commence once all funds have been drawn.
On October 24, 2018, the Company completed an offering of 2,250,461 Common Shares through the conversion of outstanding warrants at a discounted price of $2.00 . Net proceeds to the Company were $4.3 million after deducting discounts, fees, and expenses. Intrexon participated in the offering, converting 1,538,461 for gross proceeds of $3.1 million .
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10‑Q and our Annual Report on Form 10‑K for the year ended December 31, 2017, which was filed on March 8, 2018.
This discussion and analysis also contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and should be read in conjunction with the disclosures and information contained in “Risk Factors” in our Annual Report on Form 10‑K for the year ended December 31, 2017. Our actual results may differ materially from those discussed below. The following discussion and analysis is intended to enhance the reader’s understanding of our business environment. The forward-looking statements included in this Quarterly Report on Form 10‑Q are made only as of the date hereof. We are not under any obligation to, and do not intend to, publicly update or review any of these forward-looking statements, whether as a result of new information, future events, or otherwise, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized.
Overview
We believe that we are a leader in the field of biotechnology tools for improving the productivity of aquaculture. Our lead product is the AquAdvantage Salmon, which received FDA approval in 2015 as the first genetically modified animal available for sale for human consumption. We have commenced commercial activities with operations in markets where we have received regulatory approval. The first steps in our commercial plan have been implemented, including the following:
•
we received approval from the provincial regulatory authorities in Prince Edward Island for the construction of a broodstock facility to house our non-transgenic Atlantic salmon stock and a 250-metric-ton recirculating aquaculture system (“RAS”) facility to grow out our AquAdvantage Salmon, and both facilities are currently under construction;
•
we have completed our first sales of AquAdvantage Salmon to Canada from our farm site in Panama; and
▪
we purchased certain assets of the aquaculture facility of Bell Fish Company LLC, which we intend to use to grow out our AquAdvantage Salmon for sale and consumption in the United States.
We are also continuing an active search in both the United States and Canada for either an existing land-based RAS facility or a site on which to build a new facility for the commercial production of AquAdvantage Salmon.
Revenue
We generate product revenue primarily through the sales of our AquAdvantage Salmon. We may also sell excess non-transgenic salmon eggs and fry to local growers. We expect that our sales will be modest and infrequent until our grow-out facilities in Indiana and Rollo Bay are operational and at full capacity.
In the future, we believe that our revenue will depend upon the number of countries in which we have received regulatory approval for the sale of our products, the number and capacity of grow-out facilities we have in operation, and the market acceptance we achieve.
Cost of Products
Cost of products includes the labor and related costs to grow out our fish, including feed, oxygen, and other direct costs; an application of overhead; and the cost to process and ship our products to customers.
Sales and Marketing Expenses
Our sales and marketing expenses currently include personnel costs, travel, and consulting fees for market-related activities. As of September 30, 2018 , we had one employee dedicated to sales and marketing.

11


Research and Development Expenses
As of September 30, 2018 , we employed nineteen scientists and technicians at our facilities on Prince Edward Island to oversee our broodstock of AquAdvantage Salmon, as well as the lines of fish we maintain for research and development purposes. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
•
salaries and related overhead expenses for personnel in research and development functions;
•
fees paid to contract research organizations, Intrexon, and consultants who perform research for us;
•
costs related to laboratory supplies used in our research and development efforts;
•
costs related to the operation of our field trials; and
•
costs related to the grow-out of fish at the Panama site that are not capitalized in inventory.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs for employees in executive, corporate, and finance functions. Other significant general and administrative expenses include corporate governance and public market maintenance, regulatory compliance, rent and utilities, insurance, and legal services, along with pre-production and capacity utilization costs for our Indiana facility. We had nineteen employees in our general and administrative group at September 30, 2018 .
Other Income (Expense)
Interest expense includes the interest on our outstanding loans. Other income (expense) includes bank charges, fees, and interest income.
Results of Operations
Comparison of the three months ended September 30, 2018 , to the three months ended September 30, 2017 .
The following table summarizes our results of operations for the three months ended September 30, 2018 and 2017, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):
Three Months Ended
September 30,
Dollar
Change
%
Change
2018
2017
(unaudited)
Product revenue
$
11

$
—

$
11

100
%
Operating expenses:
Product costs
9

—

9

100
%
Sales and marketing
65

196

(131
)
(67
)%
Research and development
805

861

(56
)
(7
)%
General and administrative
1,852

1,382

470

34
%
Operating loss
2,720

2,439

281

12
%
Total other (income) expense
7

7

—

—
%
Net loss
$
2,727

$
2,446

$
281

11
%
Product Revenue and Product Cost
Product revenue for the three months ended September 30, 2018 , consisted of sales of non-transgenic Atlantic salmon fry. We expect that our sales will be modest and infrequent until our grow-out facilities in Indiana and Rollo Bay are operational and at full capacity.
Sales and Marketing Expenses
Sales and marketing expenses for the three months ended September 30, 2018 , were down from the corresponding period in 2017 due to lower personnel and travel costs. We expect that our sales and marketing expenses will be relatively flat until we increase our production of AquAdvantage Salmon.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2018 , were down from the corresponding period in 2017 due to a reduction in outside contract services, which were partially offset by increased field trial costs. We expect that our research and development expenses will increase as we further develop our Rollo Bay farm site and as we continue to pursue regulatory approval for additional products and additional markets.

12


General and Administrative Expenses
General and administrative expenses for the three months ended September 30, 2018 , were up from the corresponding period in 2017 due to increases in personnel, board of director fees, stock compensation charges and excess capacity at the Indiana facility as it commences start-up.
Total Other (Income) Expense
Total other (income) expense is comprised of interest on debt, bank charges and interest income for the three months ended September 30, 2018 and 2017.
Comparison of the nine months ended September 30, 2018 , to the nine months ended September 30, 2017 .
The following table summarizes our results of operations for the nine months ended September 30, 2018 and 2017, together with the changes in those items in dollars and as a percentage (all dollar amounts in thousands):
Nine Months Ended
September 30,
Dollar
Change
%
Change
2018
2017
(unaudited)
Product revenue
$
78

$
53

$
25

47
%
Operating expenses:
Product costs
72

51

21

41
%
Sales and marketing
223

607

(384
)
(63
)%
Research and development
2,664

2,517

147

6
%
General and administrative
5,067

3,453

1,614

47
%
Operating loss
7,948

6,575

1,373

21
%
Total other (income) expense
10

20

(10
)
(50
)%
Net loss
$
7,958

$
6,595

$
1,363

21
%
Product Revenue and Product Cost
Product revenue for the nine months ended September 30, 2018 , consisted of sales of AquAdvantage Salmon and sales of non-transgenic Atlantic salmon eggs and fry. We expect that our sales will be modest and infrequent until our grow-out facilities in Indiana and Rollo Bay are operational and at full capacity.
Sales and Marketing Expenses
Sales and marketing expenses for the nine months ended September 30, 2018 , were down from the corresponding period in 2017 due to lower personnel and travel costs. We expect that our sales and marketing expenses will be relatively flat until we increase our production of AquAdvantage Salmon.
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2018 , were up from the corresponding period in 2017 due to increases in personnel, supplies, and facility costs related to the partial commencement of activities at our Rollo Bay site and increased field trial costs, which were partially offset by a reduction in outside contract services. We expect that our research and development expenses will continue to increase as we further develop our Rollo Bay farm site and as we continue to pursue regulatory approval for additional products and additional markets.
General and Administrative Expenses
General and administrative expenses for the nine months ended September 30, 2018 , were up significantly from the corresponding period in 2017 due to increases in personnel and supplies primarily related to pre-production and start-up costs at our Indiana site, which were partially offset by a reduction in legal fees. We expect that our general and administrative expenses will decrease as production increases at the Indiana facility.
Total Other (Income) Expense
Total other (income) expense is comprised of interest on debt, bank charges, interest income, and a net gain on the disposal of assets for the nine months ended September 30, 2018 and 2017.

13


Liquidity and Capital Resources
Sources of Liquidity
We have incurred losses from operations since our inception in 1991, and, as of September 30, 2018 , we had an accumulated deficit of $116 million. On January 18, 2017, we completed a private placement of 2,421,073 Common Shares to Intrexon for proceeds of approximately $25 million. On January 17, 2018, we completed a public offering of 3,692,307 Common Shares and warrants to purchase 4,246,153 Common Shares for net proceeds of $10.6 million.
As of September 30, 2018 , we had a cash balance of $ 1.0 million .
On October 24, 2018, the Company completed an offering of 2,250,461 common shares through the conversion of outstanding warrants at a discounted price of $2.00. Net proceeds to the Company were $4.3 million after deducting discounts, fees, and expenses.
Cash Flows
The following table sets forth the significant sources and uses of cash for the periods set forth below (in thousands):
Nine Months Ended
September 30,
2018
2017
(unaudited)
Net cash provided by (used in):
Operating activities
$
(7,469
)
$
(6,676
)
Investing activities
(3,354
)
(17,235
)
Financing activities
11,385

25,250

Effect of exchange rate changes on cash
(24
)
54

Net increase (decrease) in cash
$
538

$
1,393

Cash Flows from Operating Activities
Net cash used in operating activities during the nine months ended September 30, 2018 , was primarily comprised of our $8.0 million net loss, offset by non-cash charges of $738 thousand, and increased by working capital uses of $249 thousand. Net cash used in operating activities during the nine months ended September 30, 2017 , was primarily comprised of our $6.6 million net loss, offset by non-cash charges of $223 thousand, and increased by working capital uses of $303 thousand.
Spending on operations increased during the current period due to headcount additions, maintenance and repair costs for our Indiana farm site, and commencement of partial activities at our Rollo Bay and Indiana farm sites. The increase in cash used by working capital in the current period was due to a reduction in accounts payable and accrued liabilities, offset by reductions in prepaid expenses, receivables and inventory.
Cash Flows from Investing Activities
During the nine months ended September 30, 2018 , we used $3.4 million for renovations to our Indiana farm site and for construction charges at our Rollo Bay site. During the same period in 2017, we used $17.2 million for construction at our Rollo Bay site and the purchase of the Indiana farm site.
Cash Flows from Financing Activities
During the nine months ended September 30, 2018 , we received approximately $10.6 million in net proceeds from the issuance of Common Shares and warrants in a public offering and $812 thousand from the exercise of warrants. This was offset by $43 thousand in the repayment of debt. During the same period in 2017, we received $25.0 million in proceeds from the issuance of Common Shares in a private placement, $257 thousand in proceeds from the issuance of term debt, and $28 thousand from the exercise of stock options. This was offset by $24 thousand in the repayment of debt.
Future Capital Requirements
We have evaluated our cash resources as of the date of issuance, including the proceeds from the warrant exercise as disclosed in Note 11, in view of our planned spending for ongoing operations, capital expenditures, and working capital for the next twelve months and have determined that our current funds will be used during the first half of 2019, primarily due to increased working capital requirements. We intend to devote a significant portion of our existing cash to our farm sites in Indiana and Rollo Bay and the continued investment in our research and development projects. We plan to seek additional financing in the form of debt or equity to fund our cash requirements.

14


We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:
•
the timing of additional regulatory approvals and permits for AquAdvantage Salmon, if any;
•
the cost to complete construction activities at our Rollo Bay site;
•
the cost to raise fish at our Indiana site; and
•
the timing of costs related to the FDA legal challenge (see “Legal Proceedings,” below).
Until such time, if ever, as we can generate positive operating cash flows, we may finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of holders of our common stock will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through government or other third-party funding; marketing and distribution arrangements; or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us.
Management’s assessment is based primarily on its ability and past experience in managing expenditures in order to conserve the Company’s cash. Management has the ability to reduce expenditures, slow-down or delay capital spending and divest assets in order to extend cash through the next twelve months.
In addition, the Company continues to seek additional financing in the form of debt or equity. However, there is no assurance the Company can be successful in securing additional financing.
Management believes it is probable that its plans will be effectively implemented and therefore, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, if we are unable to generate additional funds in the future through financings, sales of our products, government grants, loans, or from other sources or transactions, we will exhaust our resources and will be unable to maintain our currently planned operations. If we cannot continue as a going concern, our stockholders would likely lose most or all of their investment in us.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which we have prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
Item 3.  Quantitative and Qualitative Disclosures About Market Risk
The following sections provide quantitative information on our exposure to interest rate risk and foreign currency exchange risk. We make use of sensitivity analyses, which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.
Interest Rate Risk
Our primary exposure to market risk is interest rate risk associated with debt financing that we utilize from time to time to fund operations or specific projects. The interest on this debt is usually determined based on a fixed rate and is contractually set in advance. At September 30, 2018 , and December 31, 2017, we had $516 thousand and $545 thousand, respectively, in interest-bearing debt instruments on our consolidated balance sheet. All of our interest-bearing debt is at fixed rates.
Foreign Currency Exchange Risk
Our functional currency is the U.S. Dollar. The functional currency of our Canadian subsidiary is the Canadian Dollar, and the functional currency of our Panama, U.S., and Brazil subsidiaries is the U.S. Dollar. For the Canadian Subsidiary, assets and liabilities are translated at the exchange rates in effect at the balance sheet date, equity accounts are translated at the historical exchange rate, and

15


the income statement accounts are translated at the average rate for each period during the year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive loss within shareholders’ equity (deficit).
Item 4.  Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Form 10‑Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the quarter ended September 30, 2018 , the Company’s disclosure controls and procedures are effective in recording, processing, summarizing, and reporting, on a timely basis, information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act and are effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a‑15(g) and 15d‑15(f)) that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

16


PART II. OTHER INFORMATION
Item 1.  Legal Proceedings
Lawsuit Against the FDA Approval of NADA
On March 30, 2016, a coalition of non-governmental organizations filed a complaint in the United States District Court for the Northern District of California against the FDA, the United States Fish and Wildlife Service, and related individuals for their roles in the approval of AquAdvantage Salmon. The coalition, including the Centre for Food Safety and Friends of the Earth, claims that the FDA had no statutory authority to regulate genetically modified animals, and, if it did, that the agency failed to analyze and implement measures to mitigate ecological, environmental, and socioeconomic risks that could impact wild salmon and the environment, including the risk that AquAdvantage Salmon could escape and threaten endangered wild salmon stocks. This lawsuit is currently in the discovery phase of litigation.
Other than as set forth above, we are not party to any legal proceedings the outcome of which, we believe, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our future business, consolidated results of operations, cash flows, or financial position. We may, from time to time, be subject to legal proceedings and claims arising from the normal course of business activities.
Item 1A.  Risk Factors
As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10‑K for the year ended December 31, 2017, which was filed on March 8, 2018, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There are no material additional updates or changes to our risk factors since the filing of our Annual Report on Form 10‑K for the year ended December 31, 2017.
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3.  Defaults Upon Senior Securities
None.
Item 4.  Mine Safety Disclosures
Not applicable.
Item 5.  Other Information
None.

17


Item 6. Exhibits
EXHIBIT INDEX
Exhibit Number
Exhibit Description

18


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AQUABOUNTY TECHNOLOGIES, INC.
November 2, 2018
/s/ Ronald L. Stotish
Ronald L. Stotish
President, Chief Executive Officer, and Director (Principal Executive Officer)
November 2, 2018
/s/ David A. Frank
David A. Frank
Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)

19

TABLE OF CONTENTS
Part I. Financial InformationItem 1. Financial StatementsItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II. Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits

Exhibits

10.1 Offer Letter dated as of July 10, 2018, from Prince Edward Island Century 2000 Fund Inc. to AQUA Bounty Canada Inc. and accepted by AQUA Bounty Canada Inc. and AquaBounty Technologies, Inc. on August 20, 2018. 10.2 Negotiable Promissory Note dated as of October 16, 2018, issued by AQUA Bounty Canada Inc. in favor of Prince Edward Island Century 2000 Fund Inc. 10.3 Collateral Mortgage dated as of July 26, 2016, by and between AQUA Bounty Canada Inc. and Prince Edward Island Century 2000 Fund Inc. 10.4 Collateral Mortgage dated as of October 9, 2018, by and between AQUA Bounty Canada Inc. and Prince Edward Island Century 2000 Fund Inc. 10.5 General Security Agreement dated as of July 26, 2016, by and between AQUA Bounty Canada Inc. and Prince Edward Island Century 2000 Fund Inc. 10.6 Guarantee dated as of October 9, 2018, made by AquaBounty Technologies, Inc. in favor of Prince Edward Island Century 2000 Fund Inc. 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.